What is a stock summary page? Click here for an overview.
Business Description
Compugen Ltd
ISIN : IL0010852080
Description
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 35.46 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.64 | |||||
| Beneish M-Score | -5.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 63.5 | |||||
| 3-Year EBITDA Growth Rate | 26.8 | |||||
| 3-Year EPS without NRI Growth Rate | 27 | |||||
| 3-Year Book Growth Rate | -20.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.36 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 20.23 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.45 | |||||
| 9-Day RSI | 33.82 | |||||
| 14-Day RSI | 35.62 | |||||
| 3-1 Month Momentum % | 37.25 | |||||
| 6-1 Month Momentum % | 14.75 | |||||
| 12-1 Month Momentum % | -21.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.26 | |||||
| Quick Ratio | 5.26 | |||||
| Cash Ratio | 5.12 | |||||
| Days Sales Outstanding | 432.28 | |||||
| Days Payable | 122.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | -1.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.54 | |||||
| Operating Margin % | -53.44 | |||||
| Net Margin % | -51.07 | |||||
| FCF Margin % | 177.6 | |||||
| ROE % | -23.8 | |||||
| ROA % | -12.19 | |||||
| ROIC % | -74.98 | |||||
| 3-Year ROIIC % | 240.23 | |||||
| ROC (Joel Greenblatt) % | -132.07 | |||||
| ROCE % | -16.18 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 23.2 | |||||
| PS Ratio | 5.19 | |||||
| PB Ratio | 2.66 | |||||
| Price-to-Tangible-Book | 2.66 | |||||
| Price-to-Free-Cash-Flow | 2.93 | |||||
| Price-to-Operating-Cash-Flow | 2.92 | |||||
| EV-to-EBIT | -3.47 | |||||
| EV-to-EBITDA | -3.47 | |||||
| EV-to-Revenue | 1.85 | |||||
| EV-to-Forward-Revenue | 2.58 | |||||
| EV-to-FCF | 0.91 | |||||
| Price-to-GF-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 3.19 | |||||
| Price-to-Net-Cash | 3.39 | |||||
| Earnings Yield (Greenblatt) % | -28.82 | |||||
| FCF Yield % | 32.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Compugen Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27.864 | ||
| EPS (TTM) ($) | -0.16 | ||
| Beta | 3.23 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.81 | ||
| Volatility % | 74.26 | ||
| 14-Day RSI | 35.62 | ||
| 14-Day ATR ($) | 0.104586 | ||
| 20-Day SMA ($) | 1.72325 | ||
| 12-1 Month Momentum % | -21.35 | ||
| 52-Week Range ($) | 1.35 - 2.67 | ||
| Shares Outstanding (Mil) | 93.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Compugen Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Compugen Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Compugen Ltd Frequently Asked Questions
What is Compugen Ltd(CGEN)'s stock price today?
The current price of CGEN is $1.60. The 52 week high of CGEN is $2.67 and 52 week low is $1.35.
When is next earnings date of Compugen Ltd(CGEN)?
The next earnings date of Compugen Ltd(CGEN) is 2025-05-20 Est..
Does Compugen Ltd(CGEN) pay dividends? If so, how much?
Compugen Ltd(CGEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers